Drug
Botulinum Toxin Type A
Botulinum Toxin Type A: highest development phase Post-Market, developed by Galderma, Ipsen. 6 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Galderma, Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Botulinum toxin type A NCT00234546 | Post-Market | Muscle Spasticity |
| Botulinum toxin type A NCT00216411 | Post-Market | Cerebrovascular Accident |
| Botulinum toxin type A NCT06047457 | Phase 3 | Episodic Migraine |
| Botulinum toxin type A NCT01753336 | Phase 3 | Cervical Dystonia |
| Botulinum Toxin Type A NCT01308060 | Phase 3 | Canthal Lines |
| Botulinum toxin type A NCT01313299 | Phase 3 | Nervous System Disorders |
Latest
No recent events.
Follow Botulinum Toxin Type A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.